neuronal PAS domain protein 4Genealiases: Le-PAS · NXF · PASD10 · bHLHe79
Q-omics provides the consensus-scored NPAS4 profile across patient tissues and cancer cell-line models. NPAS4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NPAS4 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, NPAS4 RNA expression shows 11,675 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight UVM, COAD, and SARC as cancer lineages where NPAS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPAS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPAS4 survival associations across molecular data types. NPAS4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPAS4 RNA expression–survival associations across cancer types. High NPAS4 expression shows unfavorable associations in UVM, MESO, THYM, KICH and COAD, but favorable associations in HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NPAS4 RNA expression.
This table summarizes NPAS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NPAS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPAS4 shows lower tumor expression in COAD, STAD, KICH, UCEC, BLCA and BRCA. The COAD box plot shows higher NPAS4 RNA expression in normal versus tumor tissue (log2 FC = −0.424, t-test p < 0.001).
This table shows molecular features associated with NPAS4 in patient tissues and cancer cell lines. In patient samples, NPAS4 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, NPAS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
